Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-01-16
2007-01-16
Aulakh, Charanjit S. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S123000, C544S121000, C544S127000, C544S357000, C544S362000, C514S234500, C514S252010, C514S253030
Reexamination Certificate
active
10820487
ABSTRACT:
The present invention relates to 1,4-dihydro-4-oxo-1,8-napthpyridine analogs of the formulaand pharmaceutically acceptable salts, esters, and prodrugs thereof, wherein A, X, W and Y are substituents. The present invention relates to methods for using such compounds.
REFERENCES:
patent: 4324893 (1982-04-01), Scotese et al.
patent: 4533663 (1985-08-01), Chu
patent: 4559157 (1985-12-01), Smith et al.
patent: 4608392 (1986-08-01), Jacquet et al.
patent: 4820508 (1989-04-01), Wortzman
patent: 4938949 (1990-07-01), Borch et al.
patent: 4992478 (1991-02-01), Geria
patent: 5624924 (1997-04-01), Chu et al.
patent: 5703055 (1997-12-01), Felgner et al.
patent: 5817669 (1998-10-01), Tomita et al.
patent: 6214560 (2001-04-01), Yguerabide et al.
patent: 6528517 (2003-03-01), Hurley et al.
patent: 6645981 (2003-11-01), Ledoussal et al.
patent: 6900224 (2005-05-01), Ledoussal et al.
patent: 2002/0049223 (2002-04-01), Elmore et al.
patent: 2003/0232818 (2003-12-01), Anderson et al.
patent: 2004/0029882 (2004-02-01), Ledoussal et al.
patent: 2004/0072817 (2004-04-01), Anderson et al.
patent: 2005/0159423 (2005-07-01), Anderson et al.
patent: 02040379 (1990-12-01), None
patent: 09221424 (1997-08-01), None
patent: WO 92/03136 (1992-03-01), None
patent: WO-04/014893 (2004-02-01), None
Anantha et al., Biochemistry (1998) 37:2709-2714.
Ansell et al., Current Opinion in Biotechnology (1996) 7:89-94.
Berge et al., J. Pharm. Sci. (1977) 66:1-19.
Datta et al., JACS (2001) 123:9612-9619.
Han et al., Nucl. Acids Res. (1999) 27:537-542.
Han et al., Trends Pharm. Sci. (2000) 21:136-142.
He et al., Science (1998) 281:1509-1512.
Henegariu et al., Nature Biotech (2000) 18:345-348.
Jin and Pike, Mol. Endocrinol. (1996) 10:196-205.
Kim et al., J. of Medicinal Chemistry (2003) 46(4):571-583.
Kriz et al., Analytical Chemistry (1995) 67:2142-2144.
Qu and Chaires, Methods Enzymol (2000) 321:353-369.
Shea, Trends in Polymer Science (1994) 2:166-173.
Tomita et al., J. Med. Chem. (2002) 45:5564-5575.
Vaickus, Crit. Rev. in Oncol./Hemotol. (1991) 11:267-297.
Vlatakis et al., Nature (1993) 361:645-647.
Weitzmann et al., J. Biol. Chem. (1996) 271:20958-20964.
Zeng et al., J. Med. Chem. (1998) 41:4273-4278.
International Search Report for PCT/US04/10969, mailed on Sep. 27, 2004, 1 page.
Santilli, J. Med. Chem. (1975) 18(10):1038-1041.
Moran Terence
Schwaebe Michael
Whitten Jeffrey P.
Aulakh Charanjit S.
Cylene Pharmaceuticals, Inc.
LandOfFree
Heterocyclic substituted 1,4-dihydri-4ox9-1,8-naphthyridine... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic substituted 1,4-dihydri-4ox9-1,8-naphthyridine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic substituted 1,4-dihydri-4ox9-1,8-naphthyridine... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3821921